A Case of Uveitis in a Patient with Juvenile Myelomonocytic Leukemia Successfully Treated with Adalimumab

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with juvenile myelomonocytic leukemia due to germline CBL mutation (10% to 15%) may have a subacute course occasionally associated with autoimmune disorders, which may resemble RAS-associated autoimmune lymphoproliferative disorder. In both conditions, prognosis and standard treatment for autoimmune phenomena remain poorly understood. We report the case of a 7-year-old boy with juvenile myelomonocytic leukemia with severe steroid-dependent uveitis, who did not respond to several therapeutic attempts with immunosuppressant agents, including sirolimus, and was finally successfully treated with adalimumab. This case offers further insight into the management of autoimmune disorders in the context of predisposing genetic conditions.

Original languageEnglish
Pages (from-to)e373-e376
JournalJournal of Pediatric Hematology/Oncology
Volume42
Issue number5
DOIs
Publication statusPublished - Jul 1 2020

Keywords

  • adalimumab
  • autoimmune
  • CBL
  • JMML
  • RALD
  • RAS
  • uveitis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A Case of Uveitis in a Patient with Juvenile Myelomonocytic Leukemia Successfully Treated with Adalimumab'. Together they form a unique fingerprint.

Cite this